Neuromagen Pharma names Prof Gal Ifergane as first member to Advisory Board
24 June 2022 -

Neuromagen Pharma Ltd., an Israel-based company developing a new class of drugs for the treatment of degenerative and senescence-associated diseases, announced on Thursday that it has named Prof Gal Ifergane, head of the Neurology Department at Soroka Medical Center as its first member to the Advisory Board.

Ifergane is serving as the head of Soroka's Medical Center Neurology department. He has served as a deputy director of the Medical Center. He created the vision for and headed the development of the Brain Medicine Division, which he also presently chairs.

Gil Ben-Menachem, Neuromagen's CEO, said, 'Prof. Ifergane brings to Neuromagen extensive expertise within the neurology field. His research and clinical experience will be of outmost importance as we move forward towards the clinic. We are honoured to have Prof. Ifergane on board, and are extremely happy to have a Be'er Sheva-based key opinion leader such as him joining our ranks.'